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Keratinocytes have a pivotal role in the regulation of immune responses, but the impact of antigen presentation
by these cells is still poorly understood, particularly in a situation where the antigen will be presented only in
adult life. Here, we generated a transgenic mouse model in which keratinocytes exclusively present a myelin
basic protein (MBP) peptide covalently linked to the major histocompatibility complex class II β-chain, solely
under inﬂammatory conditions. In these mice, inﬂammation caused by epicutaneous contact sensitizer
treatment resulted in keratinocyte-mediated expansion of MBP-speciﬁc CD4+ T cells in the skin. Moreover,
repeated contact sensitizer application preceding a systemic MBP immunization reduced the reactivity of the
respective CD4+ T cells and lowered the symptoms of the resulting experimental autoimmune encephalomye-
litis. This downregulation was CD4+ T-cell–mediated and dependent on the presence of the immune modulator
Dickkopf-3. Thus, presentation of a neo self-antigen by keratinocytes in the inﬂamed, adult skin can modulate
CD4+ T-cell auto-aggression at a distal organ.
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INTRODUCTION
The observation that the type and strength of immune
responses depend on the local micro-environment of a given
tissue (Alferink et al., 1999; Matzinger, 2007) has fostered
investigations on the contribution of various tissue-speciﬁc
components to the resulting immune response. In the skin, the
prominent role of Langerhans cells (Mayerova et al., 2004;
Stoitzner et al., 2006; Nagao et al., 2012) and dermal
dendritic cells (Itano et al., 2003; Allan et al., 2006; Idoyaga
et al., 2013) in inducing antigen-speciﬁc immunity or tole-
rance is well established.
Less is known about the role of epidermal keratinocytes
in the activation or suppression of T-cell effector functions.
For example, keratinocyte-speciﬁc expression of a nominal
antigen, such as ovalbumin (OVA), led to proliferation of
OVA-speciﬁc CD4+ T cells and was able to cause symptoms
of an inﬂammatory dermatitis (Rosenblum et al., 2011).
However, in this transgenic system, OVA-derived peptides
were also presented by professional antigen-presenting cells
(APC) in the skin-draining lymph nodes, which prevented to
identify the contribution of antigen presentation by keratino-
cytes to the resulting T-cell response.
In a similar study, mice expressing a model antigen in
keratinocytes developed a graft-versus-host–like reaction after
intradermal injection of CD8+ T cells carrying the respective
speciﬁcity (Kim et al., 2009). In this case, antigen presentation
by Langerhans cells and dendritic cells was experimentally
excluded. Thus, it was proposed that keratinocytes can
directly prime naive CD8+ T cells in the adult skin (Kim
et al., 2009).
We have previously shown that CD8+ T cells with a
transgenic major histocompatibility complex (MHC) class I
Kb-speciﬁc TCR become tolerant following encounter of the
Kb antigen on keratinocytes (Alferink et al., 1998). As in this
animal model the respective TCR recognized only the intact
MHC molecule, it was proposed that T-cell stimulation occurred
through direct contact with keratinocytes. However, this
contact mainly occurs during the neonatal phase when
extensive trafﬁcking of T cells through tissues including the
skin is observed (Kimpton et al., 1995). In contrast, T-cell
migration into the healthy, adult skin is restricted (Mackay,
1993), and T cells can only inﬁltrate inﬂammatory sites (Hou
and Doherty, 1993; Tietz et al., 1998; Wang et al., 2010).
In parallel, it was also reported that CD4+ T cells can be
directly activated by keratinocytes speciﬁcally presenting
peptide–MHC class II conjugates. Inﬂammatory skin disease
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was observed in 20–40% of mice expressing such a
transgenic MHC class II I-Ab β-chain under the keratin14
promotor and a corresponding auto-reactive TCR on CD4+
T cells. In this study, keratinocytes were shown to activate and
to be the primary targets of auto-reactive CD4+ T cells (Fan
et al., 2003).
Here, we investigated whether keratinocytes that present a
sessile self-antigen in the inﬂamed, adult skin can prime
CD4+ T cells in the absence of antigen presentation by
professional APCs and whether this activation can modulate a
distant, auto-reactive T-cell response. Therefore, we gener-
ated a transgenic mouse model, in which keratinocytes
express a silent antigenic determinant, namely an encepha-
litogenic myelin basic protein peptide (MBP1-10), covalently
linked to the MHC class II IAu β-chain (Ker-MBP mice). Cell
surface presentation of this transgene product requires co-
expression of the endogenous MHC II α-chain, which needs
to be induced by inﬂammatory stimuli like for example IFN-γ
(Nickoloff and Turka, 1994). This allowed us to study the
contribution of keratinocytes to T-cell activation in the
inﬂamed skin and to the associated auto-reactivity at a
distal site in the context of experimental autoimmune
encephalomyelitis (EAE).
In the Ker-MBP mouse model, transferred MBP-speciﬁc Tg4
CD4+ T cells proliferated only in sensitized skin but not in the
draining lymph nodes. Repeated skin sensitization induced
regulatory T cells, which limited MBP-speciﬁc CD4+ T cell
reactivity and lowered EAE symptoms after MBP immuniza-
tion. Moreover, the recently described immune modulator
Dickkopf-3 (DKK3) (Papatriantafyllou et al., 2012) was found
to contribute to the downmodulation of MBP-speciﬁc CD4+
T–cell reactivity. Together, these ﬁndings suggest that self-
antigen presentation by keratinocytes under inﬂammatory
conditions can modulate auto-reactive CD4+ T–cell responses
at a distal site.
RESULTS
Generation and characterization of transgenic Ker-MBP mice
To generate a mouse model for conditional induction of a self-
antigen in the inﬂamed skin of adult mice, we fused a cDNA
encoding the MBP1-10 peptide and a glycine-serine linker to
the genomic DNA of the IAu β-chain. The central nervous
system-derived peptide MBP1-10 was chosen as a model
antigen because auto-antigens of the brain can also be found
in the skin under physiological conditions (Kormos et al.,
2011). This construct was put under the control of a keratin IV
promoter element that is known to direct expression
exclusively to keratinocytes of hair follicles (Alferink et al.,
1998; Ker-MBP, Figure 1a). The transgenic MBP-IAu β-chain is
constitutively expressed in resting keratinocytes. However,
cell surface presentation of the transgene requires co-
expression of the endogenous MHC class II α-chain, which
is absent in keratinocytes in the healthy skin but induced by
inﬂammatory stimuli like IFN-γ (Nickoloff and Turka, 1994;
Figure 1b). In order to ensure keratinocyte restricted MBP-IAu
MHC class II β-chain production, we initially conﬁrmed
tissue-speciﬁc expression of the transgene by reverse-tran-
scriptase–PCR using RNA extracted from the respective tissues
(Figure 1c). Moreover, MBP-IAu β-chain expression in
keratinocytes was assessed by immunoﬂuorescence staining
in the skin with a MBP1-10-speciﬁc rabbit anti-serum (Figure 1d).
To clarify whether surface presentation of the MBP-MHC II
complex on keratinocytes is inducible and could be recog-
nized by T cells, TCR-transgenic MBP-speciﬁc Tg4 T cells
were labeled with carboxyﬂuorescein succinimidyl ester and
transferred into Ker-MBP mice 1 day before application of the
contact sensitizers oxazolone (OXA) or diphenylcyclopre-
none (DPCP). In particular, contact sensitizers were used to
induce inﬂammation in the skin, as they were shown to be
potent inducers of MHC class II expression in keratinocytes
(Stringer et al., 1991). Five days after transfer, T cells were
isolated from draining lymph nodes and treated skin and
analyzed by ﬂow cytometry. Proliferating Tg4 T cells could be
observed in the inﬂamed skin of Ker-MBP mice but were
undetectable in draining lymph nodes (Figure 1e). As a control,
untreated Ker-MBP mice were analyzed. There, transferred Tg4
cells did not proliferate in lymph nodes and were not
detectable in the skin of these mice (Figure 1e, lower panel).
However, strong proliferation was observed in draining lymph
nodes when MBP-peptide-loaded dendritic cells were co-
injected with the transferred Tg4 T cells (Figure 1f). Thus, these
results reveal that the Ker-MBP mouse model allows us to the
study the consequences of keratinocyte restricted self-antigen
presentation in the skin, in the absence of antigen presentation
by professional APC in the draining lymph nodes.
Functional presentation of the transgenic MBP-IAu MHC II β-
chain in the skin of Ker-MBP mice only occurs upon contact
sensitizer treatment
In order to increase the low endogenous level of MBP-speciﬁc
CD4+ T cells found in the polyclonal TCR repertoire, we
crossed Ker-MBP mice to the MBP-speciﬁc TCR-transgenic
Tg4 mice (Liu et al., 1995). This allowed us to study the
functionality of the MBP-MHC class II complex presentation
by keratinocytes in vivo in more detail. Furthermore, it
enabled us to exclude accidental thymic or peripheral
presentation of the transgene, which might induce tolerance
against the MBP antigen (Alferink et al., 1998; Kurschus et al.,
2006). Analysis of the thymus revealed comparable propor-
tions of thymocyte subsets in Tg4 and Tg4xKer-MBP mice
(Figure 2a), indicating a normal T-cell development in both
mouse strains. Furthermore, CD4+ T–cell proportions, as well
as their memory differentiation status, identiﬁed by surface
expression of CD62L and CD44, were similar in in Tg4 and
Tg4xKer-MBP mice (Figure 2b), suggesting that there is no
induction of peripheral tolerance. To asses this on a func-
tional level, Ker-MBP-positive and -negative Tg4 mice were
challenged with MBP peptide in CFA. Both types of mice
showed similar levels of EAE (Figure 2c), revealing that there is
no inﬂuence of the Ker-MBP transgene on the functional
readout system of our mouse model per se. Importantly,
contact sensitizer treatment resulted in the accumulation of
CD4+ T cells in the skin of Tg4xKer-MBP mice but not in the
skin of Tg4 mice, 8 days after one single application.
However, this was not accompanied by severe skin disease
like scaling or alopecia. As well, we did not observe interface
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dermatitis or an eczematous reaction in the double-transgenic
mice (Figure 2d).
Repeated skin sensitization limits EAE symptoms in Ker-MBP
mice
Next, we asked whether treatment of Ker-MBP mice with
contact sensitizers would have a functional impact on the
following, active immunization with MBP. Untreated
Ker-MBP and wild-type (WT) mice developed comparable
EAE symptoms upon MBP1-10 immunization (Figure 3a). As
repeated exposure of T cells to self-antigens in tissues has
been reported to attenuate the severity of autoimmune
responses (Lara-Corrales and Pope, 2010; Rosenblum et al.,
2011), we decided to perform repetitive skin treatments with
a contact sensitizer before EAE induction. Indeed, four
repetitive pre-treatments with DPCP reduced the severity of
EAE symptoms in Ker-MBP mice compared with littermate
controls (Figure 3b). However, this difference was apparently
not due to a generally impaired expression of the endogenous
MHC class II α-chain in the skin of Ker-MBP mice (Figure 3c).
Reduction in the anti-MBP T–cell response in Ker-MBP mice
was not based on a general DPCP-induced immune suppres-
sion in the skin, as pre-treatment did not affect a delayed-type
hypersensitivity response to another contact sensitizer, OXA
(Figure 3d). Thus, DPCP-mediated chronic inﬂammation in
the skin of Ker-MBP mice results in continuous cell surface
presentation of the MBP peptide on keratinocytes, which in
turn downmodulates the following MBP-speciﬁc T–cell
response in the brain.
CD4+ T cells mediate the downmodulation of T-cell reactivity in
Ker-MBP mice
To clarify the mechanisms that limit the MBP-induced
autoimmunity shown in Figure 3b, it was initially investigated
whether this was associated with a dominant form of immune
regulation. EAE induced by the transfer of MBP-activated
splenocytes resulted in signiﬁcantly less severe EAE symptoms
in DPCP pre-treated Ker-MBP mice compared with non-
transgenic littermates (Figure 4a). Furthermore, CD4+
T cells were isolated from spleens of DPCP pre-treated WT
and Ker-MBP mice and transferred into WT mice. Upon MBP
immunization, lower EAE scores were observed in recipients
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Figure 1. MBP-IAu β-chain transgene expression in Ker-MBP mice is skin restricted. (a) MBP-IAu β-chain transgenic construct. (b) Schematic illustration of the
Ker-MBP mouse model. (c) Semi-Quantitative real-time reverse-transcriptase–PCR (qRT-PCR) of the MBP-IAu β-chain in indicated tissues of Ker-MBP and wild-
type (WT) mice. (d) Representative immunoﬂuorescence stains for MBP1-10 (green), keratin-15 (red), and nuclei (blue) in the skin of Ker-MBP and control mice
(Bar = 200 μm). (e) In all 5× 107 carboxyﬂuorescein succinimidyl ester (CFSE)-labeled splenocytes from Tg4 mice were transferred i.v. into Ker-MBP mice. The
next day shaved abdomen of mice was treated with oxazolone (OXA, 3%) or diphenylcycloprenone (DPCP, 2%) or was left untreated. Five days later, CFSE
proﬁles of Tg4 CD4+ T cells isolated from draining lymph nodes (LN) and the skin were analyzed (representative experiment; ND, not detected). (f) In all 5× 107
CFSE labeled Tg4 splenocytes were co-transferred with MBP1-10-peptide–loaded dendritic cells into Ker-MBP mice. Representative CFSE dilution of Tg4 T cells
from LN 5 days after transfer.
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of T cells isolated from pre-treated Ker-MBP mice compared
with animals that received T cells from pre-treated non-
transgenic littermates (Figure 4b). These ﬁndings suggest that
the downmodulation of MBP-speciﬁc T-cell reactivity in pre-
treated Ker-MBP mice was mediated by regulatory T cells.
However, we could neither observe changes in the frequency
of CD4+CD25+Foxp3+ regulatory T cells in the lymph nodes
and spleens of DPCP-treated Ker-MBP mice nor could detect
altered expression of forkhead box P3 (FOXP3) in the skin
of these mice (Figure 5c and d). Next, we analyzed the
expression levels of several immune modulators like pro-
grammed cell death 1 ligand (PD-L1) that was shown to be an
important regulator of CD8+ T-cell effector function in a
similar mouse model (Okiyama and Katz, 2014). However, no
differential expression of IL-10, transforming growth factor-β
(TGF-β), cytotoxic T–lymphocyte-associated antigen 4 and
PD-L1 could be detected in untreated or DPCP-treated skin
between WT and Ker-MBP groups (Figure 4e). We have
previously reported that the secreted protein DKK3, which is
also expressed in hair follicles (Ohyama et al., 2006),
can limit CD8+ T–cell reactivity in vitro and in vivo
(Papatriantafyllou et al., 2012). Analysis of DKK3 expression
revealed a signiﬁcant upregulation in DPCP pre-treated skin
of Ker-MBP mice compared with non-transgenic littermates
(Figure 4e). However, this upregulation was not accompanied
by an increase in the systemic DKK3 level in the serum
(Figure 4f). Moreover, no DKK3 expression in CD4+ T cells
isolated from spleen and lymph nodes of untreated and DPCP
pre-treated Ker-MBP and WT mice (Figure 4g).
Limitation of T-cell reactivity in Ker-MBP mice depends on the
presence of DKK3
In order to clarify whether DKK3 contributes to the limitation
of CD4+ T–cell reactivity in pre-treated transgenic animals,
Ker-MBP mice deﬁcient for DKK3 were established and four
times pre-treated with DPCP. In contrast to DKK3-competent
mice, pre-treatment did not result in a reduction in EAE
symptoms in DKK3-deﬁcient Ker-MBP mice in comparison to
non-transgenic Dkk3− /− littermates (Figure 5a). In addition,
we blocked DKK3 function in Ker-MBP and WT mice by
administration of a neutralizing DKK3-speciﬁc antibody
at the beginning of the DPCP treatment. Similar to the
DKK3-deﬁcient situation, we did not observe a reduction in
MBP-triggered EAE as a result of DPCP pre-treatment in
Ker-MBP mice compared with WT controls (Figure 5b). The
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Figure 2. Functional myelin basic protein peptide (MBP1-10) presentation in Ker-MBP mice only occurs upon contact sensitizer treatment. (a) Representative
dot plots of CD8 and Vβ8.2 versus CD4 expression on thymocytes of Tg4xKer-MBP and Tg4 control mice. (b) Representative dot plots of Vβ8.2 versus CD4
expression and histograms of CD44 and CD62L expression on CD4 T cells from lymph nodes of Tg4xKer-MBP and Tg4 control mice. (c) Tg4xKer-MBP and Tg4
were immunized by MBP1-10/CFA subcutaneous injection (t0) and experimental autoimmune encephalomyelitis (EAE) symptoms were monitored. Mean clinical
score± SEM is plotted over time. (n=8, not signiﬁcant). (d) Representative histology of the skin of Tg4xKer-MBP and Tg4 mice 8 days after single application of
oxazolone (3%). Inﬁltration of leukocyte populations was analyzed using hematoxylin/eosin (Bar = 100 μm), anti-MAC-3 (Bar = 100 μm), or anti-CD4 (red)
staining (Bar= 25 μm).
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absence of EAE downmodulation was again not due to altered
endogenous MHC class II expression (Figure 5c).
Finally, we investigated whether the observed changes in
EAE severity were linked with the effector function of the
respective MBP-speciﬁc CD4+ T cells. WT and Ker-MBP mice
were immunized with MBP1-10, and 7 days later splenic
T cells were re-stimulated in vitro with the respective peptide.
The percentages of MBP-speciﬁc CD4+ T cells producing
IL-2, tumor necrosis factor, and IL-17 were comparable in the
two experimental groups (Figure 5d). However, the percen-
tages of IL-2, tumor necrosis factor, and IL-17–producing
MBP-speciﬁc T cells were signiﬁcantly reduced among
in vitro re-stimulated CD4+ T cells that had been isolated
from Ker-MBP mice following four times DPCP treatment. By
contrast, the effector function of MBP-speciﬁc CD4+ T cells
from DPCP-treated Ker-MBP.Dkk3− /− mice was not compro-
mised in vitro compared with untreated controls (Figure 5d).
Thus, chronic skin inﬂammation as modeled by repeated
DPCP treatment and the associated priming of MBP-speciﬁc
CD4+ T cells by keratinocytes in the skin can reduce systemic
CD4+ T–cell reactivity in an antigen-dependent manner
through a mechanism that involves DKK3 expression.
DISCUSSION
The skin provides a ﬁrst line of defense against physical
insults, toxins, and pathogens. Therefore, immune surveil-
lance of this barrier has to be ﬁnely balanced to ensure its
integrity. Here, we asked how T cells respond to cognate
auto-antigens that are presented exclusively by keratinocytes
of the inﬂamed skin, and whether this presentation can
inﬂuence T-cell reactivity against the respective antigen in a
distant organ. Our data suggest that (i) keratinocytes can
present self-antigen to stimulate CD4+ T cells under inﬂam-
matory conditions, (ii) repeated antigen stimulation in the
inﬂamed skin leads to downmodulation of T-cell responses,
and (iii) this downmodulation is CD4+ T-cell–mediated and
depends on the expression of DKK3.
In our Ker-MBP mouse model, a MBP peptide that is covalently
linked to the MHC class II Au β-chain is exclusively and con-
stitutively expressed in keratinocytes of hair follicles. In naive
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mice carrying the Ker-MBP transgene, MBP-speciﬁc CD4+ T cells
do not seem to be aware of their cognate antigen, suggesting that
the MBP peptide is not presented under steady state conditions.
Upon skin sensitization, MBP presentation on the cell
surface of keratinocytes is enabled. If professional APCs
would take up the MBP peptide in this situation one would
expect MBP-speciﬁc T-cell proliferation in the draining lymph
nodes after migration of CD11c+ cells was induced by contact
sensitizers. However, proliferation of MBP-speciﬁc T cells was
only observed in the skin and was absent from draining lymph
nodes. These observations support the view that, in the Ker-
MBP mouse model, the MBP1-10 peptide represents a truly
sessile antigen in the skin that can be presented exclusively by
keratinocytes and only upon inﬂammation.
The cutaneous inﬂammation that was induced by a single
treatment with the contact sensitizer OXA was more potent in
Tg4xKer-MBP mice than in Tg4 mice. However, severe skin
disease, such as scaling and alopecia, was not observed in the
double-transgenic mice. This is in contrast to what was
observed in a transgenic mouse model where a nominal
antigen, such as OVA, was inducibly expressed in keratino-
cytes (Rosenblum et al., 2011). In these mice, OVA-speciﬁc
T cells caused pronounced inﬂammatory dermatitis that
spontaneously resolved after 20–30 days (Rosenblum et al.,
2011). The different results obtained in the two models might
reﬂect the fact that OVA can be presented to DO11 T cells by
professional APCs in the Ker-OVA mouse model, whereas
MBP is presented to Tg4 T cells exclusively by keratinocytes
in the Ker-MBP system.
There is increasing evidence that repeated exposure of T cells
to self-antigens in tissues attenuates the severity of autoimmune
responses (Lara-Corrales and Pope, 2010; Rosenblum et al.,
2011). Accordingly, in our mouse model, repeated applications
of DPCP that allowed for continuous availability of the MBP-
MHC class II complex on keratinocytes limited the severity of
subsequent EAE. Interestingly, DPCP is used clinically for the
treatment of alopecia areata because of its proposed immune-
modulatory capacity (Hoffmann et al., 1994).
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4 times pre-treated with DPCP (n=6). (d) Quantitative real-time reverse-transcriptase–PCR (QRT-PCR) of Foxp3 in the skin of Ker-MBP and WT mice pre-treated
like in c. Expression levels are relative to Actb (n=6). (e) QRT-PCR on RNA isolated from total skin of DPCP pre-treated or untreated Ker-MBP and WT mice.
Expression levels of indicated genes are relative to Actb (n=6–12). (f) Dickkopf-3 (DKK3) concentration in serum of untreated and 4 times DPCP pre-treated
Ker-MBP and WT mice, measured by ELISA (n=4). (g) QRT-PCR of Dkk3 in CD4+ T cells isolated from untreated and 4 times DPCP pre-treated Ker-MBP and WT
mice. As negative control, CD4+ T cells isolated from untreated Dkk3− /− mice were used. As positive control, total skin of 4 times DPCP pre-treated mice was
used (n=3).
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It was reported that epicutaneous immunization with the
auto-antigenic MBP peptide was able to inhibit the induction
of EAE (Bynoe et al., 2003). This protection was based on
CD4+ T–cell regulation but was independent of CD4+CD25+
regulatory T cells and was not mediated by immune modu-
lators such as IL-4, IL-10, or transforming growth factor-β. In
this study, the MBP peptide was shown to be presented by
professional APCs in the draining lymph nodes. It is interest-
ing that repeated tolerogenic epicutaneous applications of
MBP peptide have similar consequences as continuous MBP
peptide presentation by keratinocytes under inﬂammatory
conditions in our mouse model.
DKK3 was found to be signiﬁcantly upregulated in the skin
of DPCP-treated Ker-MBP mice compared with littermate
controls. We have recently reported that DKK3 can limit
CD8+ T-cell–mediated tumor and skin graft rejection
(Papatriantafyllou et al., 2012). DKK3 is mainly expressed at
sites that have been traditionally referred to as immune
privileged including the hair follicle (Barrantes Idel et al.,
2006; Ohyama et al., 2006; Hermann et al., 2007). It is
therefore, tempting to speculate that DKK3 may contribute to
the immunosuppressive milieu of such tissues. Here we show
that abrogation of DKK3 function was sufﬁcient to reverse the
reduction in T-cell–mediated EAE symptoms in DPCP-treated
Ker-MBP mice. Furthermore, expression of DKK3 in the skin
was associated with decreased cytokine production by MBP-
speciﬁc CD4+T cells. Whether DKK3 acts directly or indirectly
on CD4+T cells in this in vivo setting is presently unknown.
Neutralizing DKK3-speciﬁc antibodies could block the down-
modulation of CD4+T–cell reactivity when administered at the
beginning of the DPCP treatment. This ﬁnding suggests that
DKK3 is involved in the induction of the observed T-cell
regulation rather than directly suppressing CD4+T–cell reactiv-
ity in the skin. Further investigations are needed to clarify the
mechanism through which DKK3 limits CD4+T–cell reactivity.
In summary, on the basis of our newly established mouse
model, we present evidence that the induction and presenta-
tion of a self-antigen by keratinocytes during skin inﬂamma-
tion is sufﬁcient to modulate T-cell auto-reactivity at a distal
site. Keratinocytes could activate MBP-speciﬁc T cells in the
skin independent from professional APCs. Furthermore,
persistent stimulation of MBP-speciﬁc CD4+ T cells by
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Figure 5. Reduction of the myelin basic protein (MBP)-speciﬁc CD4+ T–cell response in Ker-MBP mice depends on Dickkopf-3 (DKK3). (a) Ker-MBPxDkk3− /−,
Dkk3− /−, Ker-MBP, and wild-type (WT) mice were 4 times pre-treated with diphenylcycloprenone (DPCP) before induction of experimental autoimmune
encephalomyelitis (EAE) (t0). Mean clinical score± SEM is plotted over time (data pooled from 2 individual experiments, n= 12). (b) Ker-MBP and WT mice were
4 times pre-treated with DPCP. In both groups, a measure of 500 μg of anti-Dkk3 mAb clone 4.22 was applied intraperitoneally along with the ﬁrst three DPCP
applications. One week after the fourth application, EAE was induced (t0) and symptoms were monitored. Mean clinical score± SEM is plotted over time (data
pooled from 2 individual experiments, n= 16). (c) Quantitative real-time reverse-transcriptase–PCR of H2-Aa in the skin of Ker-MBP.Dkk3− /− and Dkk3− /− mice
7 days after 4 times DPCP pre-treatment. Expression levels were calculated relative to Actb (n=6). (d) Ker-MBP and Ker-MBP.Dkk3− /− mice were 4 times pre-
treated with DPCP or left untreated and EAE was induced. Seven days later, splenocytes were in vitro re-stimulated with MBP1-10 peptide and analyzed by ﬂow
cytometry. Depicted are the percentages of IL-2, tumor necrosis factor, and IL-17–producing CD4+ T cells (data pooled from three individual experiments, n=6).
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keratinocytes in the chronically inﬂamed skin led to a
reduction in EAE symptoms. Thus, repeated antigen presenta-
tion by keratinocytes during skin inﬂammation may dampen
the respective T-cell reactivity at a distal site.
MATERIALS AND METHODS
Mice
B10.PL mice were obtained from Jackson Laboratories (Bar Harbor,
ME). TCR-transgenic Tg4 mice have been described (Acha-Orbea
et al., 1988). Dkk3 − /− mice (Barrantes Idel et al., 2006) were crossed
to a H-2KU background (B10.PL). Mice were maintained under
speciﬁc pathogen-free conditions at the German Cancer Research
Center. All animal experiments were approved by the local
government authorities (Regierungspräsidium, Karlsruhe, Germany).
Generation of transgenic Ker-MBP mice
For keratinocyte-speciﬁc expression, the 2.4 kb fragment of the
Keratin IV promoter was used (Alferink et al., 1998). The introduction of
the signal sequence and the MBP1-10-peptide (ASQKRPSQRS) into the
IAu β-chain cDNA has been described (Kurschus et al., 2006). To
assure appropriate cleavage of the signal sequence, the amino acid
sequence GDS was introduced N-terminal to the MBP-sequence. As a
substitute of natural acetylation, a glycine residue was inserted between
the GDS sequence and the MBP1-10 sequence. We replaced the cDNA
after exon 2 with the genomic DNA of the I-Ab β-chain (obtained from
RZPD, Berlin, Germany; identical with the β-chain IAu coding
sequence). The DNA construct was linearized and injected into
C57BL/6×DBA/2 F2 oocytes. Transgenic mice were backcrossed more
than 10 times to B10.PL and were crossed to Tg4 mice.
Histology
Skin tissue was ﬁxed in a zinc-based ﬁxative (Dako, Hamburg,
Germany), embedded in parafﬁn, and routinely stained with H&E.
Furthermore, sections were stained with rat anti-mouse CD4 or rat
anti-mouse MAC-3 followed by a biotinylated rabbit anti-rat IgG and
development with the LSAB-AP kit (Dako).
Immunoﬂuorescence
Skin tissue was ﬁxed with phosphate-buffered 4% formaldehyde. Five-
micrometer parafﬁn sections were de-parafﬁnized and rehydrated,
before staining with rabbit polyclonal Abs speciﬁc for MBP1-10 or
Keratin-15 followed by ﬂuorochrome-conjugated secondary Abs.
Counterstaining was performed with DAPI. Pictures were generated
on a Cell observer microscope (Zeiss, Oberkochen, Germany).
Flow cytometry
Surface antigen staining was performed according to standard
procedures. 2.5×106 splenocytes were re-stimulated with 50 μgml−1
MBP1-10 in the presence of Golgi Plug (BD Bioscience, Heidelberg,
Germany) for 6 hours, and intracellular cytokine staining was performed
with Cytoﬁx/Cytoperm reagents (BD Bioscience). Fluorochrome-labeled
mAbs were purchased from BD Bioscience. Flow cytometric analyses
were performed on a FACSCanto (BD Bioscience).
EAE induction
EAE was induced by injecting 200 μg N-terminal acetylated MBP1-10
peptide Ac-ASQKRPSQRS (Ac1-10) emulsiﬁed in 100 μl complete
Freund’s adjuvant containing 200 μg Mycobacterium tuberculosis
(Thomas Geyer, Renningen, Germany) subcutaneously. At day 1 and
2 after immunization, each mouse received 200 ng pertussis toxin i.p.
(Merck Biosciences, Darmstadt, Germany). Clinical symptoms were
scored as follows: 0, normal; 1, limp tail or hind limb weakness; 2, limp
tail and hind limb weakness; 3, partial hind limp paralysis; 4, complete
hind limb paralysis; and 5, dead or moribund, killed by investigator.
Contact sensitization
OXA (4-ethoxymethylene-2-phenyloxazol-5-one) and DPCP (2,3-
Diphenylcycloprop-2-en-1-one) were dissolved in acetone and applied
to mouse abdominal mouse skin 1 day after shaving. For single
treatment, a volume of 100 μl of a 3% OXA or a 2% DPCP (w/v)
solution was applied. For repeated DPCP treatment, a volumeof 20 μl
of a 2% solution, followed by 100 μl of a 0.1, 0.25, or 0.5% (w/v)
solution, each 1 week apart, was applied. Experimental procedures
were pursued 1 week after the last application.
Anti-Dkk3 antibody treatment
In parallel to the DPCP skin treatments, a measure of 0.5mg of the anti-
Dkk3 4.22mAb (Papatriantafyllou et al., 2012) in 200 μl phosphate-
buffered saline was applied i.p., 3 times, each 1 week apart.
T-cell proliferation in vivo
Splenocytes were incubated with 5 μM carboxyﬂuorescein succini-
midyl ester (Molecular Probes, Eugene, OR) in DPBS for 15min at
37 °C. 5×107 cells were injected into the tail vein, and 5 days later
proliferation of T cells in lymph nodes and the skin was analyzed by
ﬂow cytometry.
EAE transfer
Ten days after B10.PL, mice were immunized with MBP1-!0 in CFA,
spleens were taken out, and single-cell suspensions were prepared.
Splenocytes were cultured for 3 days in RPMI containing MBP1-10
peptide (20 μgml−1) and IL-12 (20 ngml− 1) at 37 °C and 5% CO2.
2× 107 of these cells were injected i.v. into the respective recipient
mice followed by two applications of pertussis toxin i.p. (200 ng).
T-cell transfer
CD4+ T cells were isolated from the spleen and lymph nodes of
DPCP pre-treated mice using the Dynabeads Untouched CD4+
T–cell isolation Kit (Life Technologies, Carlsbad, CA) according to the
manufacturer's instructions. 5× 105 of theses CD4+ T cells were
transferred i.v. into WT mice followed by induction of EAE via MBP1-
10/CFA immunization and i.p. pertussis toxin (200 ng) application.
Quantitative real-time reverse-transcriptase–PCR
Total RNA was extracted from the skin using the RNeasy kit (Qiagen,
Venlo, The Netherlands). RNA was reverse transcribed using the
SuperScript II kit (Invitrogen, Carlsbad, CA). Quantitative real-time
PCR was performed on an AB 7500 reverse-transcriptase–PCR
System using Absolute qPCR SYBR Green ROX Mix (Thermo
Scientiﬁc, Waltham, MA). The oligonucleotide primer sequences
were as follows: Actb-Fp: 5′-TGACAGGATGCAGAAGGAGATTA-3′;
Actb-Rp: 5′-AGCCACCGATCCACACAGA-3′; Foxp3-Fp: 5′-CACAA
CCTGAGCCTGCACAA-3′; Foxp3-Rp: 5′-TCAAATTCATCTACGGTC
CACACT-3′; Tgfb1-Fp: 5′-TGGAGCAACATGTGGAACTC-3′; Tgfb1-
Rp: 5′-CAGCAGCCGGTTACCAAG-3′; Il10-Fp: 5′-CCAGCCTGAGC
CTAGAATTCA-3′; Il10-Rp: 5′-TGGCTTCAAACCACACATAGGA-3′;
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Pd-l1-Fp: 5′-TGGACAAACAGTGACCACCAA-3′; Pd-l1-Rp: 5′-TGTC
CGGGAAGTGGTGACA-3′; Ctla4-Fp: 5′-ACTCATGTACCCACCGC
CATA-3′; Ctla4-Rp: 5′-TGGTTCTGGATCAATGACATAAAT-3′;
Dkk3-Fp: 5′-TCCCATTGCCACCTTTGG-3′; Dkk3-Rp: 5′-CCAGTTC
TCCAGCTTCAAGTACAC-3′; H2-Aa-Fp: 5′-TCTCCCTCCTGTGATC
AACA-3′; H2-Aa-Rp: 5′-CACCGTCTGCGACTGACTTG-3. Data
were calculated relative to the housekeeping gene Actb by using
the 2−ΔΔCT method.
ELISA
Mouse serum was added to anti-Dkk3 4.22 mAb-coated ﬂexible
assay plates (Greiner, Bio-One Kremsmünster, Austria). Biotinylated
goat anti-mouse Dkk3 antibody (R&D Systems, Minneapolis, MN)
was applied as detection antibody followed by streptavidin-
peroxidase (Jackson ImmunoResearch, West Grove, PA). After
washing, orthophenylene diamine substrate was applied. Reaction
was stopped with sulphuric acid. Optical densities were analyzed
with a Viktor 2 photometer (Perkin Elmer, Waltham, MA) at
490 nm.
Statistical analysis
Two tailed Student’s t-test was used unless indicated otherwise to test
signiﬁcant numerical differences between groups. Differences in EAE
progression in between two groups were analyzed using the repeated
measures analysis of variance test. Dead mice due to EAE were
scored 5 until the end of the study. P-values ofo0.05 were regarded
as statistically signiﬁcant (*Po0.05; **Po0.01; ***Po0.001).
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